Brokerages expect Kamada Ltd. (NASDAQ:KMDA) to post $24.84 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Kamada’s earnings. The highest sales estimate is $25.18 million and the lowest is $24.50 million. Kamada posted sales of $19.37 million in the same quarter last year, which suggests a positive year over year growth rate of 28.2%. The firm is scheduled to report its next earnings results on Thursday, November 9th.

According to Zacks, analysts expect that Kamada will report full year sales of $24.84 million for the current year. For the next year, analysts anticipate that the business will report sales of $126.66 million per share, with estimates ranging from $120.80 million to $132.51 million. Zacks’ sales averages are a mean average based on a survey of analysts that cover Kamada.

KMDA has been the topic of a number of analyst reports. Zacks Investment Research lowered Kamada from a “hold” rating to a “sell” rating in a report on Tuesday, July 18th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $7.00 price objective (down previously from $9.00) on shares of Kamada in a report on Wednesday, August 2nd. TheStreet lowered Kamada from a “c-” rating to a “d+” rating in a report on Tuesday, August 1st. Finally, ValuEngine lowered Kamada from a “hold” rating to a “sell” rating in a report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $8.50.

Shares of Kamada (KMDA) traded down $0.05 on Tuesday, reaching $4.65. The company’s stock had a trading volume of 40,074 shares, compared to its average volume of 49,983. Kamada has a 12 month low of $3.75 and a 12 month high of $8.61. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.95 and a current ratio of 2.85.

A number of hedge funds have recently bought and sold shares of the stock. Paulson & CO. Inc. lifted its stake in Kamada by 8.2% in the 2nd quarter. Paulson & CO. Inc. now owns 790,800 shares of the biotechnology company’s stock valued at $4,745,000 after buying an additional 60,000 shares in the last quarter. Vanguard Group Inc. lifted its stake in Kamada by 6.5% in the 2nd quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock valued at $2,810,000 after buying an additional 28,382 shares in the last quarter. Nexthera Capital LP purchased a new stake in Kamada in the 2nd quarter valued at approximately $1,805,000. Renaissance Technologies LLC lifted its stake in Kamada by 16.7% in the 1st quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock valued at $1,801,000 after buying an additional 37,800 shares in the last quarter. Finally, Worth Venture Partners LLC purchased a new stake in Kamada in the 3rd quarter valued at approximately $246,000. 7.25% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.watchlistnews.com/24-84-million-in-sales-expected-for-kamada-ltd-kmda-this-quarter/1686540.html.

About Kamada

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Get a free copy of the Zacks research report on Kamada (KMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.